Back to top

Image: Bigstock

Here's How Much a $1000 Investment in Veeva Systems Made 10 Years Ago Would Be Worth Today

Read MoreHide Full Article

For most investors, how much a stock's price changes over time is important. Not only can it impact your investment portfolio, but it can also help you compare investment results across sectors and industries.

Another thing that can drive investing is the fear of missing out, or FOMO. This particularly applies to tech giants and popular consumer-facing stocks.

What if you'd invested in Veeva Systems (VEEV - Free Report) ten years ago? It may not have been easy to hold on to VEEV for all that time, but if you did, how much would your investment be worth today?

Veeva Systems' Business In-Depth

With that in mind, let's take a look at Veeva Systems' main business drivers.

Veeva Systems Inc. is headquartered in Pleasanton, CA and provides industry cloud solutions for the global life sciences market. Its offerings span cloud software, data, artificial intelligence capabilities and business consulting, supporting customers from research and development through commercialization. Veeva operates as a single reportable segment and groups revenues into Commercial Solutions and R&D and Quality Solutions. 

Commercial Solutions include Veeva Commercial Cloud applications and Veeva Data Cloud. Key products include Veeva CRM, Vault CRM, Veeva Network and data offerings such as OpenData and Compass, along with Crossix for digital measurement. Veeva Systems has also released its advanced Veeva Commercial Cloud offering, Veeva CRM Engage Webinar, at the Veeva Commercial Summit Europe. Veeva Systems also released Veeva Vault PromoMats Brand Portal — a new digital asset management capability that helps brand managers create portals, organize and showcase content within Veeva Vault PromoMats. Veeva Systems has also announced the availability of the whole suite of commercial data products from Veeva Compass Suite for a more comprehensive understanding of patient groups and HCP-level information.

Veeva CRM is delivered on the Salesforce platform, while Vault CRM is built on the Veeva Vault platform and is the company’s migration path for existing CRM customers. R&D and Quality Solutions include Veeva Development Cloud and Veeva Quality Cloud products, which are utilized in clinical, regulatory, safety, quality and manufacturing workflows, featuring modules such as eCOA, RTSM, EDC, Safety and LIMS.

FY26 at a Glance

For fiscal 2026, VEEV registered total sales of $3.19 billion, up 16% year over year. VEEV reported adjusted earnings per share of $8.10 for fiscal 2026, up 22.7% compared with fiscal 2025.

Subscription Service revenues were $2.68 billion (84% of net sales, up 17.5% from fiscal 2025), while Professional services and other revenues grossed $511.1 million (16%, up 10%).

Bottom Line

Anyone can invest, but building a successful investment portfolio requires research, patience, and a little bit of risk. So, if you had invested in Veeva Systems, ten years ago, you're likely feeling pretty good about your investment today.

According to our calculations, a $1000 investment made in September 2016 would be worth $6,261.92, or a gain of 526.19%, as of September 22, 2026, and this return excludes dividends but includes price increases.

In comparison, the S&P 500's gained 258.96% and the price of gold went up 212.28% over the same time frame.

Going forward, analysts are expecting more upside for VEEV.

Veeva Systems continues to benefit from broad demand for life sciences cloud platforms, with R&D and Quality expansion and stronger Vault CRM execution supporting its growth outlook. Commercial momentum has broadened across CRM, content, data and Crossix, while management raised fiscal 2027 revenue and earnings expectations. Falcon and application AI add a longer-term growth avenue, but adoption and pricing remain early, and product readiness is still the limiting factor. The balance sheet remains highly liquid and supports continued repurchases. Offsetting these positives, the mature CRM market offers fewer greenfield wins, competition with Salesforce persists through the migration cycle, and newer R&D products should offset slower growth in established applications. These crosscurrents continue to support a Neutral view.

Over the past four weeks, shares have rallied 5.17%, and there have been 10 higher earnings estimate revisions in the past two months for fiscal 2026 compared to none lower. The consensus estimate has moved up as well.

Published in